Fashionable, but What is Their Real Clinical Usefulness? NLR, LMR, and PLR as a Promising Indicator in Colorectal Cancer Prognosis: A Systematic Review
Aleksandra Misiewicz,Violetta Dymicka-Piekarska
DOI: https://doi.org/10.2147/JIR.S391932
IF: 4.5
2023-01-07
Journal of Inflammation Research
Abstract:Aleksandra Misiewicz, 1, &ast Violetta Dymicka-Piekarska 2, &ast 1 Medical Diagnostic Laboratory Lab 110, Bialystok, Poland; 2 Department of Clinical Laboratory Diagnostics, Medical University of Bialystok, Bia&lstrokystok, Poland &astThese authors contributed equally to this work Correspondence: Violetta Dymicka-Piekarska, Department of Clinical Laboratory Diagnostics, Medical University of Bialystok, Waszyngtona Str. 15, Bialystok, 15-276, Poland, Tel +48 85 746 85 84, Email The link between inflammation and cancer is still an attractive subject of many studies because systemic inflammatory response has been proven to play a pivotal role in cancer progression and metastasis. The strongest relationship between chronic inflammation and cancer development is observed in colorectal cancer (CRC). The evaluation of ratios derived from the routinely performed inflammatory biomarkers shows limited performances and limited clinical utility when individually used as prognostic factors for patients with CRC. In this review, we would like to summarize the latest knowledge about the diagnostic utility of systemic inflammatory ratios: neutrophil/lymphocyte (NLR), lymphocyte/monocyte (LMR), and platelet/lymphocyte (PLR) in CRC. We focused on the papers that assessed the diagnostic utility of blood cell parameters on the basis of the area under the ROC curve published in the recent 6 years. Identification of biomarkers that are significantly associated with prognostic in cancer would help the selection of patients with a high risk of poor outcomes. Keywords: biomarkers, colorectal cancer, inflammation, prognosis Colorectal cancer (CRC) is the third most common cancer in men and women in the world (according to 2018 statistics by the World Cancer Research Found), despite significant advances in diagnosis and treatment. They account for 11% of all diagnosed cancers. 1,2 In recent years, CRC incidence has been increasing in developed countries, with the highest prevalence observed in Australia, and New Zealand, as well as in Western Europe. The lowest incidence is observed in Africa and South-Central Asia. 3 In spite of systemic improvement, the prognosis of affected patients, due to local recurrences or metastasis, is still a cause for concern in many countries. The 5-year survival rate is approximately 65% in Australia, Canada, the United States, and Western Europe. According to the Polish National Cancer Registry, the 5-year survival rate among patients with colorectal cancer in the first decade of the 21st century has increased slightly: in men from 43.3% to 47.6%, and in women from 44.1% to 49, 1%. 3 That is why it is so important to understand the key molecular elements leading to malignant invasion and metastasis, as well as to identify effective diagnostic and prognostic biomarkers. 2,4 The link between inflammation and the development of neoplastic diseases continues to be the subject of many studies. The first evidence of the involvement of chronic inflammation in the development of a neoplastic disease was provided by the works of the French surgeon Jean Nicholas Marjolin, who in 1828 observed the development of squamous cell carcinoma around an open wound accompanied by chronic inflammation. 5,6 Up to 25% of cancers are thought to be linked to chronic inflammation, whether caused by chemical or physical factors, or by infections. 7 The strongest relationship between chronic inflammation and cancer is observed in inflammatory diseases of the large intestine, ie ulcerative colitis ( colitis ulcerosa ) and Crohn's disease. 8 Their occurrence increases the risk of colorectal cancer up to 10 times. 9 In contrast, tumors that do not arise from inflammation are characterized by the presence of inflammatory cells and mediators. In this case, inflammation is the result of tumor growth. Tumors are not solely made out of mutant cells. The tumor microenvironment consists of numerous cells, for instance, the tumor stroma contains fibroblasts, endothelial cells, pericytes and mesenchymal cells among others. 10 These cells produce pro-inflammatory cytokines (IL-1, −6, −8, −10, −17, −23, TNF-α, TGF-β) and chemokines (CCL2, CXCL8, CCL11) that attract immune cells such as macrophages, neutrophils, mast cells, dendritic cells, T and B lymphocytes, and natural killer (NK) cells. Leukocytes may constitute up to 50% of the total tumor mass. 11,12 They all constitute the so-called tumor-associated systemic inflammatory response (SIR) – pivotal elements of tumor progression and can lead to the formation of micro-metastasis lesions. SIR is also associated with patient's cachexia and malnutrition which all together can promote tumor progres -Abstract Truncated-
immunology